STEPHEN MCLEOD-BRYANT: Open Payments
NPI 1669580510 · CORAL GABLES, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$604 in 22 payments from 8 companies in 2025. Trend: 2023 $368 · 2024 $883 · 2025 $604
Food & beverage: $604
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $141 |
| ACADIA Pharmaceuticals Inc | 1 | $113 |
| Janssen Pharmaceuticals, Inc | 3 | $88 |
| Teva Pharmaceuticals USA, Inc. | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| ABBVIE INC. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Alkermes, Inc. | 1 | $22 |
Products named: INGREZZA, NUPLAZID, INVEGA SUSTENNA, AUSTEDO XR, VRAYLAR, ABILIFY ASIMTUFII, REXULTI, FANAPT.
Industry payments across FL — which companies pay providers there.
